Novartis AG Release: Everolimus (RAD001) Significantly Extends Progression-Free Survival in Advanced Kidney Cancer Patients After Failure of Other Targeted Therapy

BASEL, SWITZERLAND--(Marketwire - February 28, 2008) - * Outstanding interim results cause independent data monitoring committee to immediately share findings; patients on placebo to be offered everolimus